FDA places hold on Teva, Regeneron back pain trial
The US Food and Drug Administration has placed on hold a Phase IIb study assessing Teva and Regeneron’s investigational nerve growth factor inhibitor fasinumab for chronic low back pain.
Read More
Tag: chronic back pain
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
- Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
